Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anat Stemmer-Rachamimov, M.D.

Co-Author

This page shows the publications co-authored by Anat Stemmer-Rachamimov and Scott Plotkin.
Connection Strength

2.314
  1. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 Aug; 23(8):1506-1513.
    View in: PubMed
    Score: 0.245
  2. Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology. 2018 07 10; 91(2 Suppl 1):S5-S13.
    View in: PubMed
    Score: 0.201
  3. Update from the 2013 International Neurofibromatosis Conference. . 2014 Dec; 164A(12):2969-78.
    View in: PubMed
    Score: 0.154
  4. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013; 8(3):e59941.
    View in: PubMed
    Score: 0.139
  5. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. . 2013 Mar; 161A(3):405-16.
    View in: PubMed
    Score: 0.138
  6. Expression of SMARCB1 (INI1) mutations in familial schwannomatosis. Hum Mol Genet. 2012 Dec 15; 21(24):5239-45.
    View in: PubMed
    Score: 0.134
  7. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22.
    View in: PubMed
    Score: 0.134
  8. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011 Mar 01; 29(7):e159-62.
    View in: PubMed
    Score: 0.119
  9. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009 Jul 23; 361(4):358-67.
    View in: PubMed
    Score: 0.107
  10. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16(7):e0252048.
    View in: PubMed
    Score: 0.062
  11. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021 07 14; 13(602).
    View in: PubMed
    Score: 0.062
  12. Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas. Ann Clin Transl Neurol. 2021 07; 8(7):1508-1514.
    View in: PubMed
    Score: 0.061
  13. Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathol. 2021 Jan; 141(1):117.
    View in: PubMed
    Score: 0.060
  14. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathol. 2021 01; 141(1):101-116.
    View in: PubMed
    Score: 0.059
  15. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 08 02; 20(9):1185-1196.
    View in: PubMed
    Score: 0.050
  16. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13(6):e0197350.
    View in: PubMed
    Score: 0.050
  17. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A. 2018 02 27; 115(9):E2077-E2084.
    View in: PubMed
    Score: 0.049
  18. Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol. 2018 01; 299(Pt B):326-333.
    View in: PubMed
    Score: 0.047
  19. Creation of an international registry to support discovery in schwannomatosis. . 2017 Feb; 173(2):407-413.
    View in: PubMed
    Score: 0.044
  20. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016 Aug 16; 87(7 Suppl 1):S40-8.
    View in: PubMed
    Score: 0.044
  21. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci U S A. 2015 Nov 24; 112(47):14676-81.
    View in: PubMed
    Score: 0.042
  22. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015 Jul 10; 6(19):16981-97.
    View in: PubMed
    Score: 0.041
  23. Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet. 2015 Aug; 52(8):557-62.
    View in: PubMed
    Score: 0.041
  24. Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome. Eur J Med Genet. 2014 May-Jun; 57(6):269-74.
    View in: PubMed
    Score: 0.037
  25. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
    Score: 0.035
  26. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology. 2012 Dec; 32(6):611-6.
    View in: PubMed
    Score: 0.032
  27. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. . 2012 Jan; 158A(1):24-41.
    View in: PubMed
    Score: 0.032
  28. Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics. 2009 Jul 09; 2:42.
    View in: PubMed
    Score: 0.027
  29. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009 Aug; 29(15):4250-61.
    View in: PubMed
    Score: 0.027
  30. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008 Feb; 29(2):278-92.
    View in: PubMed
    Score: 0.024
  31. Diagnostic criteria for schwannomatosis. Neurology. 2005 Jun 14; 64(11):1838-45.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.